OCUL vs. TGTX, KRYS, VRNA, OGN, BHVN, RARE, SRRK, ALVO, ADMA, and VKTX
Should you be buying Ocular Therapeutix stock or one of its competitors? The main competitors of Ocular Therapeutix include TG Therapeutics (TGTX), Krystal Biotech (KRYS), Verona Pharma (VRNA), Organon & Co. (OGN), Biohaven (BHVN), Ultragenyx Pharmaceutical (RARE), Scholar Rock (SRRK), Alvotech (ALVO), ADMA Biologics (ADMA), and Viking Therapeutics (VKTX). These companies are all part of the "pharmaceutical products" industry.
Ocular Therapeutix vs.
Ocular Therapeutix (NASDAQ:OCUL) and TG Therapeutics (NASDAQ:TGTX) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, risk, community ranking, earnings, institutional ownership, dividends, analyst recommendations, valuation and profitability.
In the previous week, Ocular Therapeutix and Ocular Therapeutix both had 3 articles in the media. Ocular Therapeutix's average media sentiment score of 0.76 beat TG Therapeutics' score of 0.49 indicating that Ocular Therapeutix is being referred to more favorably in the media.
TG Therapeutics has higher revenue and earnings than Ocular Therapeutix. TG Therapeutics is trading at a lower price-to-earnings ratio than Ocular Therapeutix, indicating that it is currently the more affordable of the two stocks.
TG Therapeutics has a net margin of -5.42% compared to Ocular Therapeutix's net margin of -283.74%. TG Therapeutics' return on equity of -8.32% beat Ocular Therapeutix's return on equity.
59.2% of Ocular Therapeutix shares are owned by institutional investors. Comparatively, 58.6% of TG Therapeutics shares are owned by institutional investors. 3.5% of Ocular Therapeutix shares are owned by insiders. Comparatively, 10.5% of TG Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Ocular Therapeutix has a beta of 1.23, suggesting that its share price is 23% more volatile than the S&P 500. Comparatively, TG Therapeutics has a beta of 2.24, suggesting that its share price is 124% more volatile than the S&P 500.
TG Therapeutics received 221 more outperform votes than Ocular Therapeutix when rated by MarketBeat users. Likewise, 76.33% of users gave TG Therapeutics an outperform vote while only 70.14% of users gave Ocular Therapeutix an outperform vote.
Ocular Therapeutix currently has a consensus target price of $16.71, suggesting a potential upside of 117.07%. TG Therapeutics has a consensus target price of $40.67, suggesting a potential upside of 28.29%. Given Ocular Therapeutix's stronger consensus rating and higher probable upside, equities analysts clearly believe Ocular Therapeutix is more favorable than TG Therapeutics.
Summary
TG Therapeutics beats Ocular Therapeutix on 11 of the 17 factors compared between the two stocks.
Get Ocular Therapeutix News Delivered to You Automatically
Sign up to receive the latest news and ratings for OCUL and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Ocular Therapeutix Competitors List
Related Companies and Tools
This page (NASDAQ:OCUL) was last updated on 2/1/2025 by MarketBeat.com Staff
